02-18-2010

curasan AG: New US subsidiary for orthopaedics

Kleinostheim, Germany, 18th February 2010 – curasan AG, listed in the General Standard of the Deutsche Börse AG (ISIN: DE 000 549 453 8), is commencing the sale, through a subsidiary, of its synthetic bone regeneration material Cerasorb® M Ortho in the United States ...

12-09-2009

curasan AG receives license for Osbone®

Kleinostheim, Germany, 9th December 2009 - curasan AG, which is listed in General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), has received CE certification and, therefore, marketing authorization throughout Europe of the synthetic bone replacement material Osbone®...

11-16-2009

curasan AG signs a research agreement with Ben-Gurion University

Kleinostheim, Germany, 16th November 2009 – curasan AG, which is listed on the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), has signed a research and development agreement with the Ben-Gurion University of the Negev (BGU), Israel...

10-15-2009

curasan AG received licence for ATR®

Kleinostheim, Germany, 15 October 2009 – curasan AG, which is listed on the
General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8),
has been received CE certification and, therefore, marketing authorization for
the ATR® (Advanced Tissue Regeneration) product...

12-11-2007

Curasan AG: US-Subsidiary on the road to Success

curasan Inc., Research Triangle Park, North Carolina, USA, wholly owned subsidiary of curasan AG, Kleinostheim, is ahead of  its business development schedule and is near a break-even point as 2007 closes...

06-14-2007

Curasan AG: REVOIS® All-in-One Dental Implant System Registered in the U.S.

curasan AG, a German leader in regenerative medicine, has obtained FDA clearance for its REVOIS® All-in-One dental implant system, permitting the sale of the system in the U.S...

03-26-2007

Curasan AG: Worldwide distribution rights for Epi-Guide®

Kleinostheim, 26 March, 2007 – curasan AG (WKN 549 453 8) has been granted worldwide distribution rights by Kensey Nash Corporation, USA, for Epi-Guide®, their bioresorbable membrane...

06-20-2006

curasan AG markets innovative GPI System

Kleinostheim, 20 June 2006 – curasan AG (WKN 549 453) is launching the Guided Positioning Implant System (GPIS), which will allow implantologists to reduce treatment times per patient by around 50%. This will open up tremendous opportunities for dental implant specialists to enhance internal efficiency levels.

06-19-2006

curasan AG: Premium-standard certification

Kleinostheim, 19 June 2006 – curasan AG (WKN 549 453) is now certified in accordance with the new standard DIN EN ISO 13485:2003 Medical Devices – Quality Management Systems – Requirements for Regulatory Purposes.

06-15-2005

Curasan Increases its Lead with New Clinical Data

Cerasorb ® ties with the gold standard in a multi-centre study

Kleinostheim, Germany, 15th June, 2005 – Cerasorb® synthetic bone regeneration material, produced by curasan AG, equals autogenous bone where therapy is concerned. This is the result of a prospective, randomised multi-centre study headed by Professor György Szabó, Budapest , Hungary and recently published in the renowned Journal of Oral and Maxillofacial Implants (JOMI, Vol. 20, 371-381, June 2005) ...